U.S. Markets open in 7 hrs 50 mins

CytRx Corporation (CYTR)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.68+0.01 (+1.19%)
At close: 4:00PM EDT
People also watch
GALECRISCVMCYCCCTIC
Full screen
Previous Close0.67
Open0.70
Bid0.00 x
Ask0.00 x
Day's Range0.67 - 0.70
52 Week Range0.36 - 2.67
Volume3,190,946
Avg. Volume8,292,326
Market Cap103.4M
Beta1.65
PE Ratio (TTM)-1.28
EPS (TTM)-0.53
Earnings DateJul 27, 2017 - Jul 31, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • PR Newswire15 days ago

    CytRx Announces Reshaping of Clinical and Regulatory Executive Team

    LOS ANGELES, June 13, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Shanta Chawla, M.D., who ...

  • Accesswire19 days ago

    Today's Research Reports on Stocks to Watch: CytRx and Hydrogenics Corporation

    NEW YORK, NY / ACCESSWIRE / June 9, 2017 / CytRx's shares saw a big gaining day yesterday after the company announced a big regulatory pathway update about aldoxorubicin, a tumor-targeted doxorubicin conjugate ...

  • PR Newswire20 days ago

    CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas

    LOS ANGELES, June 8, 2017 /PRNewswire/ -- CytRx Corporation (CYTR) a biopharmaceutical research and development company specializing in oncology, today announced an update on the regulatory pathway for a New Drug Application (NDA) submission for aldoxorubicin in soft tissue sarcomas (STS). The Company plans to submit a rolling NDA under section 505(b)(2) to the FDA for aldoxorubicin as a treatment for STS. The 505(b)(2) pathway is designed for a new drug that contains the same active ingredient as a previously approved drug, also known as a reference drug. For aldoxorubicin, doxorubicin is the reference drug. The NDA submission is not reliant solely on the recently completed Phase 3 clinical trial in STS or overall survival results. Rather, CytRx's completed pharmacokinetic clinical trial, Phase 2b and Phase 3 trials in STS, along with preclinical safety and efficacy studies, will serve as "scientific bridges" between aldoxorubicin and doxorubicin.